Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2017

View Archived Issues

Takeda and NuBiyota enter collaboration for the development of microbiome therapeutics

Discovery and preclinical characterization of novel MPS1 inhibitor CCT-289346

Ono describes selective ITK inhibitors for inflammatory disorders

Dual EZH1/2 inhibitor OR-S-1 shows promise in models of multiple myeloma, mantle cell lymphoma

Emulate signs multi-year collaborative agreement with the FDA

HER2-TTC, a novel HER2-targeted Th-227 conjugate with promising efficacy in cancer models

Arqule receives clearance for ARQ-531 phase I study

Meprin B involved in N-terminal truncated beta-amyloid generation in the brain

AzurRx Biopharma's phase II study of MS-1819 expected to complete Q3 2017

6XFAD Alzheimer's disease model displays both amyloid and tau pathology

FDA issues EAU for Nanobiosym Diagnostics' Zika virus test

Medix obtains approval to initiate phase III study of tesofensine

Mission Therapeutics and University of Oxford receive research grant from MJFF

FDA grants approval for Ingrezza capsules for adults with tardive dyskinesia

ARGX-110 enters phase II testing as a monotherapy in patients with relapsed/refractory CTCL

GlaxoSmithKline identifies novel IDO-1 inhibitors

LegoChem Biosciences patents anti-CD19 and anti-EGFR antibody-drug conjugates

Janssen describes novel BACE inhibitors

SOTIO gains rights to oncology program from Lead Discovery Center

BMS and Apexigen to evaluate Opdivo in combination with APX-005-M

Keystone Nano announces progress on RNA delivery using its proprietary NanoJackets

CDCN and Janssen enter a research collaboration to conduct a proteomics study of iMCD

National Immunotherapy Coalition formed to accelerate next-generation standard of care in cancer

French authorities grant Eyevensys approval to advance EyeCET platform

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...